ALGN vs BCRX
Align Technology vs BioCryst Pharmaceuticals, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
BCRX
BioCryst Pharmaceuticals, Inc.
55
Watch
| Metric | ALGN | BCRX |
|---|
| AI Score |
73
|
55
|
| Price |
$172.86
|
$10.35
|
| P/E Ratio |
30.03×
|
-7.19×
|
| ROE |
10.1%
|
-221.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
23.5%
|
| Debt / Equity |
0.03×
|
-0.90×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
75.0
|
| Beta |
1.653
|
0.554
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus BCRX.
ALGN leads by 18 points.
ALGN scores 73/100 (Buy) versus BCRX at 55/100 (Watch).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
BCRX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value